search
Back to results

Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE) (iLiNS-DOSE)

Primary Purpose

Malnutrition

Status
Completed
Phase
Phase 3
Locations
Malawi
Study Type
Interventional
Intervention
Lipid-based nutrient supplement, 10gM
Lipid-based nutrient supplement, 20gM
Lipid-based Nutrient Supplement, 20gNoM
Lipid-based nutrient supplement, 40gM
Lipid-based Nutrient Supplement, 40gNoM
Maize-soy flour
Sponsored by
Tampere University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malnutrition focused on measuring Stunting, Growth failure, Malnutrition, Lipid based nutrient supplement, LNS, Prevention, Malawi, Sub-Saharan Africa, Dietary supplementation, Efficacy

Eligibility Criteria

167 Days - 197 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Signed informed consent from at least one guardian
  • Age 5.50 months to 6.49 months
  • Availability during the period of the study.
  • Permanent resident of Mangochi District Hospital or Namwera Health Centre catchment area

Exclusion Criteria:

  • Weight for length Z score (WLZ) < -2.0
  • Presence of oedema
  • Severe anaemia (Hb<50 g / l)
  • Severe illness warranting hospital referral
  • History of allergy towards peanut
  • History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care
  • Concurrent participation in any other clinical trial

Sites / Locations

  • University of Malawi, College of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Other

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

ST-DI (Delayed intervention)

LNS-10gM

LNS-20gM

LNS-20gNoM

LNS-40gM

LNS-40gNoM

Arm Description

1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring

Outcomes

Primary Outcome Measures

Change in length-for-age Z-score (LAZ, based on WHO 2005 MGRS) between enrollment and 18 months of age
Incidence of serious adverse events during the study period

Secondary Outcome Measures

Change in weight-for-age (WAZ) and weight-for-length (WLZ) Z-scores
Incidence of stunting, underweight, and wasting
Prevalence of reduced appetite
Energy intake from complementary foods
Incidence of laboratory-confirmed malaria infection
Incidence of caregiver-reported morbidity
Immune function (measured by humoral immunity towards measles vaccination)
Change in hemoglobin and micronutrient status (iron status, measured by zinc protoporphyrin (ZPP); plasma zinc; plasma vitamin A; B-vitamins and related metabolites; urine iodine
Proportion with anaemia at 18 months of age
Change in erythrocyte essential fatty acid (EFA) concentration (measured from a subsample of 400 participants)
Neuro-behavioral development (timing of acquisition of the certain skills and more comprehensive analysis at the age of 18 months)
Incidence of all adverse events during the study period

Full Information

First Posted
July 21, 2009
Last Updated
May 26, 2015
Sponsor
Tampere University
Collaborators
Kamuzu University of Health Sciences, University of California, Davis, Bill and Melinda Gates Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00945698
Brief Title
Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)
Acronym
iLiNS-DOSE
Official Title
A Two-centre, Randomised, Single-blind, Parallel Group Controlled Trial, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With Different Doses and Formulations of Lipid-based Nutrient Supplements (LNS)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tampere University
Collaborators
Kamuzu University of Health Sciences, University of California, Davis, Bill and Melinda Gates Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The use of lipid-based nutrients (LNS), such as Nutributter or fortified spread (FS), have been associated with improved growth and development outcomes among infants in Ghana and Malawi. Modified versions of such supplements have been developed to improve their nutrient density and quality and to lower their costs. Such modified products have proven acceptable to infants and their guardians in Malawi and Ghana. In the present trial, the investigator aim to identify the lowest growth-promoting daily dose of modified LNS. Additionally, the investigators will test a hypothesis that LNS that does not contain milk promotes growth as well as milk-containing LNS when given for 12 months at a 10-40 g daily dose to 6-18 month old infants in rural Malawi.
Detailed Description
Six-month old healthy infants are identified through community surveys in the study area. 1920 infants meeting set criteria are randomised into receiving the following intervention between 6 and 18 months of age: 1) standard treatment from 6-18 months (i.e.no supplements, with delayed intervention between 18-30 months of age (ST-DI), 2) 10 g / day milk-containing LNS (LNS-10gM), 3) 20 g / day milk-containing LNS (LNS-20gM), 4) 20 g / day milk-free LNS (LNS-20gNoM), 5) 40 g / day milk-containing LNS, (LNS-40gM) 6) 40 g / day milk-free LNS (LNS-40gNoM). The families receive the food supplements at 2-weekly intervals and the participants undergo a morbidity evaluation weekly, a limited development assessment at 4-weekly intervals and anthropometric evaluation at 26-week intervals and laboratory analyses at enrollment and at 18 months. Growth outcome analyses are done at 18 and at 42 months of age.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malnutrition
Keywords
Stunting, Growth failure, Malnutrition, Lipid based nutrient supplement, LNS, Prevention, Malawi, Sub-Saharan Africa, Dietary supplementation, Efficacy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1920 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ST-DI (Delayed intervention)
Arm Type
Other
Arm Description
1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Arm Title
LNS-10gM
Arm Type
Experimental
Arm Description
140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Arm Title
LNS-20gM
Arm Type
Experimental
Arm Description
280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Arm Title
LNS-20gNoM
Arm Type
Experimental
Arm Description
280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Arm Title
LNS-40gM
Arm Type
Experimental
Arm Description
560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Arm Title
LNS-40gNoM
Arm Type
Experimental
Arm Description
560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based nutrient supplement, 10gM
Intervention Description
140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based nutrient supplement, 20gM
Intervention Description
280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based Nutrient Supplement, 20gNoM
Intervention Description
280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based nutrient supplement, 40gM
Intervention Description
560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based Nutrient Supplement, 40gNoM
Intervention Description
560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Intervention Type
Dietary Supplement
Intervention Name(s)
Maize-soy flour
Intervention Description
No food supplement during the primary trial period (6 to 18 months of age) 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring
Primary Outcome Measure Information:
Title
Change in length-for-age Z-score (LAZ, based on WHO 2005 MGRS) between enrollment and 18 months of age
Time Frame
Primarily 12 months after enrollment (age 18 months), secondarily 36 months after enrollment (age 42 months)
Title
Incidence of serious adverse events during the study period
Time Frame
12 months after enrollment (age 18 months)
Secondary Outcome Measure Information:
Title
Change in weight-for-age (WAZ) and weight-for-length (WLZ) Z-scores
Time Frame
Primarily 12 months after enrollment (age 18 months), secondarily 36 months after enrollment (age 42 months)
Title
Incidence of stunting, underweight, and wasting
Time Frame
Primarily 12 months after enrollment (age 18 months), secondarily 36 months after enrollment (age 42 months)
Title
Prevalence of reduced appetite
Time Frame
Daily assessment during 12 month supplementation
Title
Energy intake from complementary foods
Time Frame
3 and 9 months after enrollment (age 9 and 15 months)
Title
Incidence of laboratory-confirmed malaria infection
Time Frame
12 months after enrollment (age 18 months)
Title
Incidence of caregiver-reported morbidity
Time Frame
Daily assessment during 12 month supplementation
Title
Immune function (measured by humoral immunity towards measles vaccination)
Time Frame
12 months after enrollment (age 18 months)
Title
Change in hemoglobin and micronutrient status (iron status, measured by zinc protoporphyrin (ZPP); plasma zinc; plasma vitamin A; B-vitamins and related metabolites; urine iodine
Time Frame
12 months after enrollment (age 18 months)
Title
Proportion with anaemia at 18 months of age
Time Frame
12 months after enrollment (age 18 months)
Title
Change in erythrocyte essential fatty acid (EFA) concentration (measured from a subsample of 400 participants)
Time Frame
12 months after enrollment (age 18 months)
Title
Neuro-behavioral development (timing of acquisition of the certain skills and more comprehensive analysis at the age of 18 months)
Time Frame
Limited assessment every 4 weeks during the 12 months supplementation, more comprehensive at age 18 months
Title
Incidence of all adverse events during the study period
Time Frame
12 months after enrollment (age 18 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
167 Days
Maximum Age & Unit of Time
197 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed informed consent from at least one guardian Age 5.50 months to 6.49 months Availability during the period of the study. Permanent resident of Mangochi District Hospital or Namwera Health Centre catchment area Exclusion Criteria: Weight for length Z score (WLZ) < -2.0 Presence of oedema Severe anaemia (Hb<50 g / l) Severe illness warranting hospital referral History of allergy towards peanut History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care Concurrent participation in any other clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per Ashorn, MD, PhD
Organizational Affiliation
University of Tampere Medical School
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kenneth Maleta, MBBS, PhD
Organizational Affiliation
Kamuzu University of Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Malawi, College of Medicine
City
Mangochi
Country
Malawi

12. IPD Sharing Statement

Citations:
PubMed Identifier
18400716
Citation
Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. Am J Clin Nutr. 2008 Apr;87(4):929-38. doi: 10.1093/ajcn/87.4.929.
Results Reference
background
PubMed Identifier
18606932
Citation
Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, Ashorn P. Complementary feeding with fortified spread and incidence of severe stunting in 6- to 18-month-old rural Malawians. Arch Pediatr Adolesc Med. 2008 Jul;162(7):619-26. doi: 10.1001/archpedi.162.7.619. Erratum In: Arch Pediatr Adolesc Med. 2008 Oct;162(10):942.
Results Reference
background
PubMed Identifier
19056572
Citation
Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, Ashorn P. Postintervention growth of Malawian children who received 12-mo dietary complementation with a lipid-based nutrient supplement or maize-soy flour. Am J Clin Nutr. 2009 Jan;89(1):382-90. doi: 10.3945/ajcn.2008.26483. Epub 2008 Dec 3.
Results Reference
background
PubMed Identifier
31010435
Citation
Bendabenda J, Patson N, Hallamaa L, Ashorn U, Dewey KG, Ashorn P, Maleta K. Does anthropometric status at 6 months predict the over-dispersion of malaria infections in children aged 6-18 months? A prospective cohort study. Malar J. 2019 Apr 22;18(1):143. doi: 10.1186/s12936-019-2778-y.
Results Reference
derived
PubMed Identifier
30593271
Citation
Bendabenda J, Patson N, Hallamaa L, Mbotwa J, Mangani C, Phuka J, Prado EL, Cheung YB, Ashorn U, Dewey KG, Ashorn P, Maleta K. The association of malaria morbidity with linear growth, hemoglobin, iron status, and development in young Malawian children: a prospective cohort study. BMC Pediatr. 2018 Dec 28;18(1):396. doi: 10.1186/s12887-018-1378-2.
Results Reference
derived
PubMed Identifier
29349922
Citation
Kumwenda C, Hemsworth J, Phuka J, Ashorn U, Arimond M, Maleta K, Prado EL, Haskell MJ, Dewey KG, Ashorn P. Association between breast milk intake at 9-10 months of age and growth and development among Malawian young children. Matern Child Nutr. 2018 Jul;14(3):e12582. doi: 10.1111/mcn.12582. Epub 2018 Jan 19.
Results Reference
derived
PubMed Identifier
28978680
Citation
Adams KP, Ayifah E, Phiri TE, Mridha MK, Adu-Afarwuah S, Arimond M, Arnold CD, Cummins J, Hussain S, Kumwenda C, Matias SL, Ashorn U, Lartey A, Maleta KM, Vosti SA, Dewey KG. Maternal and Child Supplementation with Lipid-Based Nutrient Supplements, but Not Child Supplementation Alone, Decreases Self-Reported Household Food Insecurity in Some Settings. J Nutr. 2017 Dec;147(12):2309-2318. doi: 10.3945/jn.117.257386. Epub 2017 Oct 4.
Results Reference
derived
PubMed Identifier
27474016
Citation
Prado EL, Abbeddou S, Adu-Afarwuah S, Arimond M, Ashorn P, Ashorn U, Brown KH, Hess SY, Lartey A, Maleta K, Ocansey E, Ouedraogo JB, Phuka J, Some JW, Vosti SA, Yakes Jimenez E, Dewey KG. Linear Growth and Child Development in Burkina Faso, Ghana, and Malawi. Pediatrics. 2016 Aug;138(2):e20154698. doi: 10.1542/peds.2015-4698.
Results Reference
derived
PubMed Identifier
26956611
Citation
Bendabenda J, Alho L, Ashorn U, Cheung YB, Dewey KG, Vosti SA, Phuka J, Maleta K, Ashorn P. The effect of providing lipid-based nutrient supplements on morbidity in rural Malawian infants and young children: a randomized controlled trial. Public Health Nutr. 2016 Jul;19(10):1893-903. doi: 10.1017/S1368980016000331. Epub 2016 Mar 9.
Results Reference
derived
PubMed Identifier
26740684
Citation
Hemsworth J, Kumwenda C, Arimond M, Maleta K, Phuka J, Rehman AM, Vosti SA, Ashorn U, Filteau S, Dewey KG, Ashorn P, Ferguson EL. Lipid-Based Nutrient Supplements Increase Energy and Macronutrient Intakes from Complementary Food among Malawian Infants. J Nutr. 2016 Feb;146(2):326-34. doi: 10.3945/jn.115.215327. Epub 2016 Jan 6.
Results Reference
derived
PubMed Identifier
26063066
Citation
Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, Phiri N, Phiri TE, Vosti SA, Zeilani M, Kumwenda C, Bendabenda J, Pulakka A, Ashorn P. Provision of 10-40 g/d Lipid-Based Nutrient Supplements from 6 to 18 Months of Age Does Not Prevent Linear Growth Faltering in Malawi. J Nutr. 2015 Aug;145(8):1909-15. doi: 10.3945/jn.114.208181. Epub 2015 Jun 10.
Results Reference
derived
PubMed Identifier
25995276
Citation
Ashorn U, Alho L, Arimond M, Dewey KG, Maleta K, Phiri N, Phuka J, Vosti SA, Zeilani M, Ashorn P. Malawian Mothers Consider Lipid-Based Nutrient Supplements Acceptable for Children throughout a 1-Year Intervention, but Deviation from User Recommendations Is Common. J Nutr. 2015 Jul;145(7):1588-95. doi: 10.3945/jn.114.209593. Epub 2015 May 20.
Results Reference
derived
PubMed Identifier
24368436
Citation
Kumwenda C, Dewey KG, Hemsworth J, Ashorn P, Maleta K, Haskell MJ. Lipid-based nutrient supplements do not decrease breast milk intake of Malawian infants. Am J Clin Nutr. 2014 Mar;99(3):617-23. doi: 10.3945/ajcn.113.076588. Epub 2013 Dec 24.
Results Reference
derived
Links:
URL
http://www.medcol.mw/
Description
College of Medicine homepage

Learn more about this trial

Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)

We'll reach out to this number within 24 hrs